Seeking Alpha
 

Merck & Co Inc. (MRK)

- NYSE
  • Feb. 1, 2013, 7:01 AM
    Merck (MRK): Q4 EPS of $0.83 beats by $0.01. Revenue of $11.73B beats by $0.27B. (PR)
    | 1 Comment
  • Feb. 1, 2013, 12:05 AM
    Notable earnings before Friday’s open: AON, BEAM, BEN, BPO, CVX, HCLP, IR, LM, LYB, MAT, MRK, NOV, NS, NWL, PRGO, TSN, WETF, XOM
    | Comment!
  • Jan. 31, 2013, 5:30 PM
    Notable earnings before Friday’s open: AON, BEAM, BEN, BPO, CVX, HCLP, IR, LM, LYB, MAT, MRK, NOV, NS, NWL, PRGO, TSN, WETF, XOM
    | Comment!
  • Jan. 25, 2013, 2:56 PM
    The FDA has approved an application by Merck (MRK +0.7%) to switch the status of the prescription patch Oxytrol, a treatment for overactive-bladder, to an over-the-counter item for women. The OTC patch, which will remain a prescription-only product for men, will be available this fall.
    | 1 Comment
  • Jan. 25, 2013, 9:26 AM
    Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from drug partner Merck (MRK), which started a late-stage study of THLD's pancreatic cancer drug. TH-302 is an investigational hypoxia-targeted drug designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers.
    | 1 Comment
  • Jan. 24, 2013, 11:45 AM
    Cubist Pharmaceuticals (CBST +3.1%) moves up today after reporting an in-line Q4 on a 16% jump in total sales. Net earnings more than quintupled however, as the drug developer racked up much stronger sales, and last year's results were weighed down by higher income-tax provisions. Sales of Cubicin, an intravenous antibiotic for skin and bloodstream infections, jumped 14% to $216M in the U.S.
    | Comment!
  • Jan. 23, 2013, 4:12 PM
    Cubist Pharma (CBST): Q4 EPS of $0.48 in-line. Revenue of $245.9M (+16% Y/Y) misses by $0.52M. Shares +0.8% AH. (PR)
    | Comment!
  • Jan. 23, 2013, 12:05 AM
    Notable earnings after Wednesday’s close: AAPL, ALTR, AMGN, BKW, CBST, CCI, FBC, FFIV, HXL, INVN, JEC, LOGI, LRCX, LSI, MIPS, MLNX, NE, NFLX, PLCM, SWFT, SNDK, SYK, SYMC, TER, URI, VAR, WDC
    | Comment!
  • Jan. 22, 2013, 5:35 PM
    Notable earnings after Wednesday’s close: AAPL, ALTR, AMGN, BKW, CBST, CCI, FBC, FFIV, HXL, INVN, JEC, LOGI, LRCX, LSI, MIPS, MLNX, NE, NFLX, PLCM, SWFT, SNDK, SYK, SYMC, TER, URI, VAR, WDC
    | 3 Comments
  • Jan. 18, 2013, 12:45 PM
    Midday top 10 gainers: GFED +19%. DOM +12%. BTUI +11%. LIFE +11%. ONP +10%. ZA +10%. SGOC +9%. DQ +9%. MOV +9%. PRTS +9%.
    Midday top 10 Losers: TELOZ -10%. HMNY -10%. TESS -9%. VOC -9%. COF -8%. CTC -8%. SINO -8%. TSRX -7%. BOSC -7%. FNSR -7%.
    | Comment!
  • Jan. 18, 2013, 10:46 AM
    Antibacterial-drug developer Trius Therapeutics (TSRX -8.22%) slips after pricing a 6.3M share secondary offering at $4.75 a share, a 9% discount to yesterday's close. The company made the announcement late yesterday without any details as to its size or scope. TSRX has a market cap of around $213M with a 39.4M share float.
    | Comment!
  • Jan. 18, 2013, 9:10 AM
    Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
    Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
    | 2 Comments
  • Jan. 17, 2013, 5:40 PM
    After-hours top gainers, as of 5:15 p.m.: AM +9%. ARAY +4%. SOXS +3%. EGLE +3%. ONXX +2%.
    After-hours top losers: COF -8%. TSRX -6%. PATH -5%. INTC -4%. MAKO -3%.
    | Comment!
  • Jan. 17, 2013, 5:04 PM
    Trius Therapeutics (TSRX) announces a secondary offering, no details as to the actual size or terms of the offering have been disclosed. Citigroup and Leerink Swann are acting as joint book-running managers and Baird is acting as a co-lead manager. Shares -5.5% AH.
    | Comment!
  • Jan. 8, 2013, 4:24 AM
    Merck (MRK) could be interested in acquiring Bausch & Lomb, with Merck CEO Kenneth Frazier saying "It's something that's worth thinking about." Any bid for Bausch & Lomb, whose owner, Warburg Pincus, hopes to get at least $10B in a sale, would be something of an about-turn for Frazier, as he previously said Merck isn't interested in large pharmaceuticals acquisitions. (previous)
    | 4 Comments
  • Jan. 7, 2013, 5:33 PM
    The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.
    | 2 Comments
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.